Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
J Alzheimers Dis ; 34(2): 509-18, 2013.
Article in English | MEDLINE | ID: mdl-23241554

ABSTRACT

Intracerebroventricular (icv) streptozotocin (STZ) administration induces pathological and behavioral alterations similar to those observed in Alzheimer's disease (AD) and is thus considered an experimental model of sporadic AD. Since caffeine (an adenosine receptor antagonist) and selective antagonists of adenosine A2A receptors modify the course of memory impairment in different amyloid-ß-based experimental models of AD, we now tested the impact of caffeine on STZ-induced dementia and associated neurodegeneration in the hippocampus as well as on the expression and density of adenosine receptors. Adult male rats received a bilateral infusion of saline or STZ (3 mg/kg, icv), which triggered memory deficits after four weeks, as gauged by impaired object recognition memory. This was accompanied by a reduced NeuN immunoreactivity in the hippocampal CA1 region and an increased expression and density of adenosine A2A receptors (A2AR), but not A1R, in the hippocampus. Caffeine consumption (1 g/L in the drinking water starting 2 weeks before the STZ challenge) prevented the STZ-induced memory impairment and neurodegeneration as well as the upregulation of A2AR. These findings provide the first demonstration that caffeine prevents sporadic dementia and implicate the control of central A2AR as its likely mechanism of action.


Subject(s)
Caffeine/administration & dosage , Dementia/prevention & control , Disease Models, Animal , Hippocampus/drug effects , Memory Disorders/prevention & control , Receptor, Adenosine A2A , Adrenergic alpha-2 Receptor Antagonists/administration & dosage , Animals , Dementia/metabolism , Dementia/pathology , Hippocampus/metabolism , Hippocampus/pathology , Male , Memory Disorders/pathology , Neurons/drug effects , Neurons/pathology , Rats , Rats, Wistar , Receptor, Adenosine A2A/biosynthesis , Up-Regulation/drug effects , Up-Regulation/physiology
3.
Behav Brain Res ; 218(1): 80-6, 2011 Mar 17.
Article in English | MEDLINE | ID: mdl-21108973

ABSTRACT

Stress affects learning and memory processes and sensitivity to stress greatly varies between individuals. We studied behavioral and neurobiological effects of unpredictable subchronic stress (USCS) in two behavioral extremes of mice from the same strain (CF1) selected by their exploratory behavior of the central arena of an open field. The top and bottom 25% explorers were classified as low exploratory (LE) and high exploratory (HE) mice, respectively. The open field task, the novel object recognition task (NOR), sucrose intake and tail suspension task were evaluated in LE and HE groups exposed to USCS for two weeks or control conditions. Also serum corticosterone and hippocampal BDNF and S100B levels were analyzed. Both stressed groups exhibited less exploratory activity when submitted to USCS, but their difference in exploratory behavior remained. This short stress protocol did not induce changes in sucrose intake or immobility in the tail suspension task. Also, LE mice exhibited impaired NOR performance after USCS, whereas HE mice changed their pattern of exploration towards less exploration of the familiar object. HE had lower corticosterone levels than LE mice, but corticosterone levels increased after stress only in HE mice. Hippocampal BDNF in LE was lower than in HE but decreased after USCS only in HE mice, whereas S100B levels were not different between groups and did not change with USCS. In conclusion, our results suggest that individual differences in exploratory behavior in rodents from the same strain influence cognitive and biochemical response to stress.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Corticosterone/blood , Exploratory Behavior/physiology , Hippocampus/metabolism , Memory/physiology , Stress, Physiological/physiology , Stress, Psychological/physiopathology , Analysis of Variance , Animals , Behavior, Animal/physiology , Enzyme-Linked Immunosorbent Assay , Male , Mice , Phenotype , Stress, Psychological/metabolism
4.
Brain Res ; 1367: 122-9, 2011 Jan 07.
Article in English | MEDLINE | ID: mdl-20977897

ABSTRACT

Considering the importance of a deeper understanding of the effect throughout life of opioid analgesia at birth, our objective was to determine whether morphine administration in early life, once a day for 7 days in 8-day-old rats, alters the nociceptive response over the short (P16), medium (P30), and long term (P60) and to evaluate which system is involved in the altered nociceptive response. The nociceptive responses were assessed by the formalin test, and the behavior analyzed was the total time spent in biting and flicking of the formalin-injected hindpaw, recorded during the first 5 min (phase I) and from 15-30 min (phase II). The morphine group showed no change in nociceptive response at P16, but at P30 and P60, the nociceptive response was increased in phase I, and in both phases, respectively. At P30 and P60, the animals received a non-steroidal anti-inflammatory drug (indomethacin) or NMDA receptor antagonist (ketamine) 30 min before the formalin test. The increase in the nociceptive response was completely reversed by ketamine, and partially by indomethacin. These results indicate that early morphine exposure causes an increase in the nociceptive response in adult life. It is possible that this lower nociception threshold is due to neuroadaptations in nociceptive circuits, such as the glutamatergic system. Thus, this work demonstrates the importance of evaluating clinical consequences related to early opioid administration and suggests a need for a novel design of agents that may counteract opiate-induced neuroplastic changes.


Subject(s)
Analgesics, Opioid/therapeutic use , Behavior, Animal/drug effects , Formaldehyde/adverse effects , Morphine/administration & dosage , Morphine/therapeutic use , Pain/chemically induced , Pain/drug therapy , Age Factors , Analgesics, Opioid/administration & dosage , Analysis of Variance , Anesthetics, Dissociative/administration & dosage , Animals , Animals, Newborn , Disease Models, Animal , Ketamine/administration & dosage , Male , Pain Measurement/methods , Rats , Rats, Wistar
5.
Prog Neuropsychopharmacol Biol Psychiatry ; 35(1): 169-76, 2011 Jan 15.
Article in English | MEDLINE | ID: mdl-21044657

ABSTRACT

Methylphenidate (MPH) is the preferred treatment used for attention-deficit/hyperactivity disorder (ADHD). Recently, misuse for MPH due to its apparent cognitive enhancer properties has been reported. Adenosine is a neuromodulator known to exert influence on the dopaminergic neurotransmission, which is the main pharmacological target of MPH. We have reported that an overdosage of MPH up-regulates adenosine A(1) receptors in the frontal cortex, but this receptor was not involved in its anxiolytic effects. In this study, the role of adenosine A(1) receptor was investigated on MPH-induced effects on aversive and recognition memory in adult mice. Adult mice received acute and chronic (15 days) administration of methylphenidate (5mg/kg, i.p.), or an acute overdosage (50mg/kg, i.p) in order to model misuse. Memory was assessed in the inhibitory avoidance and object recognition task. Acute administration 5mg/kg improved whereas 50mg/kg disrupted recognition memory and decreased performance in the inhibitory avoidance task. Chronic administration did not cause any effect on memory, but decreased adenosine A(1) receptors immunocontent in the frontal cortex. The selective adenosine A(1) receptor antagonist, (DPCPX 1mg/kg, i.p.), prevented methylphenidate-triggered recognition memory impairment. Our findings showed that recognition memory rather than aversive memory was differently affected by acute administration at both doses. Memory recognition was fully impaired by the overdosage, suggesting that misuse can be harmful for cognitive functions. The adenosinergic system via A(1) receptors may play a role in the methylphenidate actions probably by interfering with dopamine-enhancing properties of this drug.


Subject(s)
Central Nervous System Stimulants/toxicity , Memory Disorders , Methylphenidate/toxicity , Receptor, Adenosine A1/metabolism , Recognition, Psychology/drug effects , Adenosine A1 Receptor Antagonists/administration & dosage , Analysis of Variance , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Escape Reaction/drug effects , Exploratory Behavior/drug effects , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Hippocampus/metabolism , Inhibition, Psychological , Male , Memory Disorders/chemically induced , Memory Disorders/metabolism , Memory Disorders/prevention & control , Mice , Recognition, Psychology/physiology , Xanthines/administration & dosage
6.
Brain Res ; 1357: 62-9, 2010 Oct 21.
Article in English | MEDLINE | ID: mdl-20699089

ABSTRACT

In recent years misuse of methylphenidate (MPH) has been reported. The main pharmacological target of methylphenidate is the dopaminergic system. Adenosine is a neuromodulator that influences the dopaminergic neurotransmission, but studies on MPH and adenosine are still lacking. In this study, adult mice were acutely treated with MPH (5mg/kg, i.p.) and to model misuse, they received an acute overdosage (50mg/kg, i.p). The involvement of adenosine A(1) receptors in anxiety-related behavior and locomotor and exploratory activity was examined. The administration of methylphenidate (5 and 50mg/kg) 30 min before the exposure to open field arena did not modify locomotor activity. The anxiolytic-like behavior was observed with both doses of MPH as revealed by the increase on the number of entries and the time spent in the open arms in the elevated plus-maze. Pre treatment with selective adenosine A(1) receptor antagonist (DPCPX 1mg/kg, i.p.) did not prevent anxiolytic effect caused by MPH 50mg/kg. Immunoblotting of frontal cortex and hippocampal extracts revealed that MPH 50mg/kg increased 88% adenosine A(1) receptor density in the frontal cortex. Extracts from hippocampus did not reveal any differences in the adenosine A(1) receptor density. Our findings ruled out the participation of adenosine A(1) receptors on the MPH-triggered anxiolytic effects. However, the density of adenosine A(1) receptors increased in a brain area strictly involved in the MPH-mediated effects. Thus, the adenosinergic system may play a role in the methylphenidate actions in the central nervous system.


Subject(s)
Anxiety/drug therapy , Frontal Lobe/metabolism , Hippocampus/metabolism , Methylphenidate/pharmacology , Motor Activity/drug effects , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Antagonists/pharmacology , Analysis of Variance , Animals , Anxiety/metabolism , Blotting, Western , Central Nervous System Stimulants/pharmacology , Male , Mice , Motor Activity/physiology , Xanthines/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...